As one of the nation’s leading physicians, Daniel D. Karp, MD brings a wealth of clinical and research expertise in both oncology and hematology. Recognized as one of the leading oncologists in the world, Dr. Karp is currently Medical Director of the Clinical Translational Research Center (CTRC) at The University of Texas MD Anderson Cancer Center in Houston.
Dr. Karp focused a great deal of his clinical work on lung cancer and other thoracic tumors from 2002-2012. In 2012 he assumed his current dual role as MD Anderson Principal Investigator for the UT Houston multidisciplinary Clinical Translational Science Award (CTSA) grant as well as Medical Director for MD Anderson’s Cancer Therapy & Research Center (CTRC). He says “this has provided me an exciting opportunity to better coordinate my patient care, clinical research, and educational efforts.” As a member of the Investigational Cancer Therapeutics Department, Dr. Karp treats patients with a wide variety of tumors.
He has been the principal and co-principal investigator on numerous clinical trials for new drugs including breast cancer, lung cancer, epithelial ovarian cancer, and renal cell carcinoma. Dr. Karp has made important contributions in evaluating the safety of combination therapies for effective cancer treatments as well as novel immunotherapies.
In addition to his clinical work, Dr. Karp serves as one of the country’s most influential mentors and educators. Currently, he is Professor at the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Previously, he taught at numerous leading universities and institutions, including Dartmouth Medical School, Boston University School of Medicine, Tufts University School of Medicine and Beth Israel Deaconess Medical Center.
Dr. Karp has authored and co-authored over 80 peer-reviewed and original research articles published in high impact medical journals including the NEJM, JAMA, Journal of Oncology Practice, and Open Journal of Thoracic Surgery. He is a highly sought after conference speaker and presenter, appearing at numerous national and international conferences and symposiums and an active member of many professional organizations including the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and the American Medical Informatics Association (AMIA).
Dr. Karp graduated from Harvard College and received his medical degree from the Duke University School of Medicine. He was awarded numerous postgraduate and clinical fellowships, including at the Sidney Farber Cancer Institute in Boston.
Named as one of Houston’s Top Doctors every year for more than a decade, Dr. Karp has been listed as one of America’s top oncologists since 2007 by the Consumer Research Council of America.